Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development

There is a major unmet need to assess the prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression.